The PE Ratio as of December 2024 (TTM) for Merus N.V. (MRUS) is -10.53

According to Merus N.V.’s latest financial reports and current stock price. The company's current PE Ratio is -10.53. This represents a change of -17.33% compared to the average of -12.74 of the last 4 quarters.

Merus N.V. (MRUS) Historical PE Ratio (quarterly & annually)

How has MRUS PE Ratio performed in the past?

The mean historical PE Ratio of Merus N.V. over the last ten years is -7.48. The current -10.53 PE Ratio has changed 13.98% with respect to the historical average. Over the past ten years (40 quarters), MRUS's PE Ratio was at its highest in in the December 2014 quarter at 0. The PE Ratio was at its lowest in in the June 2022 quarter at -43.22.

Merus N.V. (MRUS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Merus N.V. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Merus N.V. (MRUS) Average PE Ratio

How has MRUS PE Ratio performed in the past?

The current PE Ratio of Merus N.V. (MRUS) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Merus N.V. (MRUS) PE Ratio vs. Peers

How is MRUS’s PE Ratio compared to its peers?

Merus N.V.’s PE Ratio is less than Anebulo Pharmaceuticals, Inc. (-4.09), less than Adagene Inc. (-2.59), less than Acrivon Therapeutics, Inc. Common Stock (-3.15), less than AnaptysBio, Inc. (-2.44), less than Mineralys Therapeutics, Inc. (-3.92), greater than Crinetics Pharmaceuticals, Inc. (-15.55), less than Inhibrx Biosciences, Inc. (0.14), less than Lyell Immunopharma, Inc. (-0.77), less than Kronos Bio, Inc. (-0.67), less than Kura Oncology, Inc. (-3.93), less than Protagonist Therapeutics, Inc. (14.68), less than Replimune Group, Inc. (-4.55), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), greater than Vaxcyte, Inc. (-21.22), less than Larimar Therapeutics, Inc. (-3.90), less than Syndax Pharmaceuticals, Inc. (-3.83), less than Sutro Biopharma, Inc. (-1.24),

Build a custom stock screener for Merus N.V. (MRUS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Merus N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Merus N.V. (MRUS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Merus N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.